Cargando…
PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target
Urothelial cancer (UC) is one of the most common cancers in Europe and is also one of the costliest to treat. When first line therapies show initial success, around 50% of cancers relapse and proceed to metastasis. In this study we assessed the Protein inhibitor of activated signal transducers and a...
Autores principales: | Erb, Holger Hans Hermann, Ebert, Marlies, Kuhn, Ronja, Donix, Lukas, Haferkamp, Axel, Seed, Robert Ian, Jüngel, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804980/ https://www.ncbi.nlm.nih.gov/pubmed/31639157 http://dx.doi.org/10.1371/journal.pone.0224085 |
Ejemplares similares
-
Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
por: Erb, Holger H. H., et al.
Publicado: (2020) -
DESY: PIA taking over
Publicado: (1979) -
Minute Hæmorrhages in the Pia Mater
por: Sheldon, T. Steele
Publicado: (1883) -
Note on the Anatomy of the Pia Mater
por: Tuke, J. Batty
Publicado: (1882) -
Note on the Anatomy of the Pia Mater
por: Tuke, J. Batty
Publicado: (1882)